{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:55:41Z","timestamp":1792104941522,"version":"4.4.0"},"reference-count":22,"publisher":"Microbiology Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.1099\/jmm.0.029470-0","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T21:52:09Z","timestamp":1298584329000},"page":"1213-1217","source":"Crossref","is-referenced-by-count":64,"title":["Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile"],"prefix":"10.1099","volume":"60","author":[{"given":"Farah","family":"Babakhani","sequence":"first","affiliation":[{"name":"Optimer Pharmaceuticals, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Gomez","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Robert","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sears","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2280-2282.2004"},{"key":"r2","article-title":"Resistance development, cross-resistance, and synergy studies of OPT-80","volume-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA","author":"Babakhani","year":"2004"},{"key":"r3","article-title":"Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118)","volume-title":"Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA","author":"Babakhani","year":"2007"},{"key":"r4","first-page":"M11","year":"2007","journal-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"r6","article-title":"Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients","volume-title":"Abstracts of the 48th Infectious Disease Society of America Annual Meeting, Vancouver, Canada","author":"Crook","year":"2010"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1086\/592981"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"r9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","article-title":"Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial","volume":"117","author":"Johnson","year":"1992","journal-title":"Ann Intern Med"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn269"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-07"},{"key":"r12","article-title":"A randomised, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection","volume-title":"Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland","author":"Louie","year":"2009b"},{"key":"r13","article-title":"Target and mechanism of the transcription inhibitor lipiarmycin","volume-title":"Presented at the Biophysical Society 48th Annual Meeting, Baltimore, MD, USA","author":"Mekler","year":"2004"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.485614"},{"key":"r15","first-page":"A-115","article-title":"OPT-80 versus vancomycin in Clostridium difficile infection: results of a randomized clinical trial","volume-title":"Gastroenterology","volume":"136","author":"Miller","year":"2009"},{"key":"r16","article-title":"The impact of hospital-onset healthcare facility associated Clostridium difficile infection (CDI) in community hospitals: surpassing methicillin-resistant Staphylococcus aureus (MRSA) as the new superbug","volume-title":"Program and Abstracts of the 5th Decennial International Conference on Healthcare-Associated Infections (ICHAI), Atlanta, Georgia","author":"Miller","year":"2010"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1159\/000104471"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2164"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-07"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(79)90459-5"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(75)80047-7"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.042010-0"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.029470-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T11:20:17Z","timestamp":1585912817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.029470-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.029470-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}